PTPRT
PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
Overview
May be involved in both signal transduction and cellular adhesion in the CNS.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming JSI-124 and Stattic. Open Targets scores its association with cancer at 0.72 (direct and indirect evidence; datatypes literature 0.94, animal model 0.62, genetic association 0.32, somatic mutation 0.90). IntOGen calls it a driver in 8 cohorts (7 activating, 1 loss-of-function), covering Oesophageal Adenocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Ovarian Epithelial Tumour, Pancreatic Adenocarcinoma and others.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
- 1 · What it is
PTPRT (Receptor-type tyrosine-protein phosphatase T) is an enzyme. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Head and neck squamous cell carcinoma, Oesophageal cancer, Gastric & gastro-oesophageal junction cancer and 5 more.
- 2 · What goes wrong in cancer
May be involved in both signal transduction and cellular adhesion in the CNS. Location: Membrane (UniProt).
- 3 · How drugs use it
No product in this corpus aims at PTPRT yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:9682 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O14522 (protein name, function text, keywords and locations (REST API)); CIViC gene PTPRT (1 evidence items, 0 assertions, 1 variants; diseases: Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000196090 (association with cancer (MONDO_0004992) 0.72; per-cancer scores at or above 0.5: gastric cancer 0.54, oesophageal cancer 0.54, ovarian cancer 0.50, melanoma 0.59, thyroid cancer 0.52, neuroendocrine neoplasm 0.52 (GraphQL API, CC0)); IntOGen PTPRT (driver in 8 cohorts (Act 7, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
May be involved in both signal transduction and cellular adhesion in the CNS. Location: Membrane (UniProt). Locus 20q12-q13.11 (HGNC).
- Head and neck squamous cell carcinoma: CIViC evidence names this disease; IntOGen driver in 1 cohort (HNSC)
- Oesophageal cancer: Open Targets association 0.54 with oesophageal cancer (MONDO_0007576); IntOGen driver in 2 cohorts (ESCA)
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.54 with gastric cancer (MONDO_0001056); IntOGen driver in 1 cohort (STAD)
- Ovarian cancer: Open Targets association 0.50 with ovarian cancer (MONDO_0008170); IntOGen driver in 1 cohort (OVT)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 2 therapies; IntOGen calls it an activating (Act) driver in 7 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"PTPRT" OR ABSTRACT:"PTPRT" OR TITLE:"protein tyrosine phosphatase receptor type T" OR ABSTRACT:"protein tyrosine phosphatase receptor type T" OR TITLE:"Receptor-type tyrosine-protein phosphatase T" OR ABSTRACT:"Receptor-type tyrosine-protein phosphatase T" OR TITLE:"RPTPrho" OR ABSTRACT:"RPTPrho" OR TITLE:"KIAA0283" OR ABSTRACT:"KIAA0283") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PTPRT, not a curated reading list.